The ‘Sanming Model’: Bad Omen Or Hope For Pharma In China?
Pharma executives in China may soon get an earful of the name Sanming, as the populist healthcare reform model that began at the small city in Fujian is rolled out nationwide and impacts profoundly how drugs are tendered, priced and distributed.
You may also be interested in...
A new dual receipting system, a potential registry for sales reps, and rules over false advertisements and promotion are just some of the many and growing challenges pressuring pharna corporate compliance officers in China, experts attending a recent conference said.
Tough new rules from China’s State Council have put the country’s one million medical reps into limbo as their employers scrabble to get to grips with broad curbs on sales activities.
Manufacturers beware, the rollout of a new receipts system could impact how drugs are distributed and sold to public hospitals in China over the course of the new year.